Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1993 2
1994 4
1995 4
1996 2
1997 2
1998 2
1999 1
2000 10
2001 10
2002 10
2003 7
2004 9
2005 11
2006 12
2007 15
2008 25
2009 32
2010 26
2011 18
2012 31
2013 23
2014 16
2015 19
2016 36
2017 17
2018 24
2019 26
2020 16
Text availability
Article attribute
Article type
Publication date

Search Results

362 results
Results by year
Filters applied: . Clear all
Page 1
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence.
Barker HE, Paget JT, Khan AA, Harrington KJ. Barker HE, et al. Among authors: harrington kj. Nat Rev Cancer. 2015 Jul;15(7):409-25. doi: 10.1038/nrc3958. Nat Rev Cancer. 2015. PMID: 26105538 Free PMC article. Review.
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby RF, Harrington KJ; KEYNOTE-040 investigators. Cohen EEW, et al. Among authors: harrington kj. Lancet. 2019 Jan 12;393(10167):156-167. doi: 10.1016/S0140-6736(18)31999-8. Epub 2018 Nov 30. Lancet. 2019. PMID: 30509740 Clinical Trial.
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Docampo LCI, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Jayaprakash V, Li L, Gillison ML. Ferris RL, et al. Among authors: harrington kj. Oral Oncol. 2018 Jun;81:45-51. doi: 10.1016/j.oraloncology.2018.04.008. Epub 2018 Apr 17. Oral Oncol. 2018. PMID: 29884413 Free PMC article. Clinical Trial.
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Hong RL, González Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D; KEYNOTE-048 Investigators. Burtness B, et al. Among authors: harrington kj. Lancet. 2019 Nov 23;394(10212):1915-1928. doi: 10.1016/S0140-6736(19)32591-7. Epub 2019 Nov 1. Lancet. 2019. PMID: 31679945 Clinical Trial.
The immunological consequences of radiation-induced DNA damage.
Wilkins AC, Patin EC, Harrington KJ, Melcher AA. Wilkins AC, et al. Among authors: harrington kj. J Pathol. 2019 Apr;247(5):606-614. doi: 10.1002/path.5232. Epub 2019 Feb 15. J Pathol. 2019. PMID: 30632153 Review.
CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.
Gillison ML, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Li L, Ferris RL. Gillison ML, et al. Among authors: harrington kj. Oncologist. 2018 Sep;23(9):1079-1082. doi: 10.1634/theoncologist.2017-0674. Epub 2018 Jun 4. Oncologist. 2018. PMID: 29866947 Free PMC article. Clinical Trial.
Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age.
Saba NF, Blumenschein G Jr, Guigay J, Licitra L, Fayette J, Harrington KJ, Kiyota N, Gillison ML, Ferris RL, Jayaprakash V, Li L, Brossart P. Saba NF, et al. Among authors: harrington kj. Oral Oncol. 2019 Sep;96:7-14. doi: 10.1016/j.oraloncology.2019.06.017. Epub 2019 Jul 3. Oral Oncol. 2019. PMID: 31422216 Free article. Clinical Trial.
The transformation of radiation oncology using real-time magnetic resonance guidance: A review.
Hall WA, Paulson ES, van der Heide UA, Fuller CD, Raaymakers BW, Lagendijk JJW, Li XA, Jaffray DA, Dawson LA, Erickson B, Verheij M, Harrington KJ, Sahgal A, Lee P, Parikh PJ, Bassetti MF, Robinson CG, Minsky BD, Choudhury A, Tersteeg RJHA, Schultz CJ; MR Linac Atlantic Consortium and the ViewRay C2T2 Research Consortium. Hall WA, et al. Among authors: harrington kj. Eur J Cancer. 2019 Nov;122:42-52. doi: 10.1016/j.ejca.2019.07.021. Epub 2019 Oct 12. Eur J Cancer. 2019. PMID: 31614288 Review.
Immunological impact of cell death signaling driven by radiation on the tumor microenvironment.
Rodriguez-Ruiz ME, Vitale I, Harrington KJ, Melero I, Galluzzi L. Rodriguez-Ruiz ME, et al. Among authors: harrington kj. Nat Immunol. 2020 Feb;21(2):120-134. doi: 10.1038/s41590-019-0561-4. Epub 2019 Dec 23. Nat Immunol. 2020. PMID: 31873291 Review.
International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma.
Lee AW, Ng WT, Pan JJ, Poh SS, Ahn YC, AlHussain H, Corry J, Grau C, Grégoire V, Harrington KJ, Hu CS, Kwong DL, Langendijk JA, Le QT, Lee NY, Lin JC, Lu TX, Mendenhall WM, O'Sullivan B, Ozyar E, Peters LJ, Rosenthal DI, Soong YL, Tao Y, Yom SS, Wee JT. Lee AW, et al. Among authors: harrington kj. Radiother Oncol. 2018 Jan;126(1):25-36. doi: 10.1016/j.radonc.2017.10.032. Epub 2017 Nov 15. Radiother Oncol. 2018. PMID: 29153464 Clinical Trial.
362 results
Jump to page
Feedback